Workshop to discuss multispecialty concepts on managing diabetes with CV, renal disease
Click Here to Manage Email Alerts
A group of leading experts in cardiology, endocrinology and nephrology will gather for a workshop to discuss best practices for managing diabetes with cardiorenal metabolic diseases, with the goal of creating a new consensus statement.
The 2-day workshop, Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases, is designed to develop a multispecialty consensus on managing conditions at the intersection of cardiology, endocrinology and nephrology. The workshop is available by invitation only to experts and supporters, who will have the opportunity to provide input during Q&A sessions and participate in an open townhall discussion. The task force will operate within a think tank, the Diabetes Cardiorenal & Metabolism Institute, or DCMi, which is also associated with Metabolic Endocrine Education Foundation, a 501c3 charitable organization.
The event will take place in-person and virtually Friday and Saturday at the Grand Hyatt DFW in Dallas.
“What is happening this weekend is an education activity, where we will study what should be the parameters covered for an eventual clinical practice recommendation,” Endocrine Today Editorial Board Member Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, medical director and principal investigator of the Metabolic Institute of America in Tarzana, California, and chair of the task force, told Healio. “The specialties now converge. A drug like the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca), for example, is a drug for endocrinologists, cardiologists and nephrologists. How should it be used? How do you reconcile the different needs? All of these large outcomes trials for these drugs that bring these specialists together have created a lot of confusion on what to do and how best to do it.”
Contemporary CV outcome trials transcend the traditional single medical field and reach across the multiple disciplines of the cardiorenal-metabolic space, Handelsman said in an interview. No single medical society is capable of developing multifaceted, comprehensive guidance, he said.
The initiative’s goal is to “fill the void” and develop a multispecialty consensus, he said, with clinical recommendations that will target specialists and primary care physicians, with focus on nonexperts, making the recommendations clinical and simple to implement. The recommendations will be published in a peer-reviewed journal and will be available free for education, Handelsman said.
The task force working group members, all volunteers, are known experts in the diabetes and cardiometabolic space, including past presidents and senior leaders of major societies like the American Diabetes Association, American Heart Association, the American Association of Clinical Endocrinology, the Heart Failure Society of America, American College of Cardiology, Kidney Disease Improving Global Outcomes, and others.
The agenda includes 20 topic areas that span the three specialties, including lifestyle, education, lipids, technology, tests to assess comorbidities, hypertension, hyperglycemia and hypoglycemia, anticoagulation, and inflammation, as well as contemporary prevention of conditions such as nonalcoholic fatty liver disease, atherosclerotic CVD, HF and chronic kidney disease.
“It is important for the cardiologist, the endocrinologist, the nephrologist, for all of us to come to an understanding — what is important in management of such a patient?” Handelsman said. “You cannot focus on one condition, one disease. You need to see the whole patient.”
For more information on the workshop meeting or the DCMi, visit www.DCRMI.com.
Collapse
Read more about
Click Here to Manage Email Alerts